Pricing Log in Create free account

Evommune Inc. (EVMN) vs Lexeo Therapeutics, Inc. (LXEO)

Evommune Inc. and Lexeo Therapeutics, Inc. are both Biotechnology companies. Evommune Inc. and Lexeo Therapeutics, Inc. are of similar size ($226.6M and $215.2M). Across the 10 metrics below, Lexeo Therapeutics, Inc. leads on 6 and Evommune Inc. on 4.

Valuation

Metric EVMN LXEO Biotechnology median
P/E n/m n/m 8.42
P/S n/m n/m 10.01
P/B 0.77 1.01 2.21
Price to free cash flow n/m n/m 21.01
EV/EBITDA n/m n/m 0.61
EV/Sales n/m n/m 9.41
Earnings yield (186.00%) (41.67%) (31.85%)
Free cash flow yield (34.84%) (37.54%) (24.58%)

Profitability

Metric EVMN LXEO Biotechnology median
Gross margin — 0.00% 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (141.99%) (46.76%) (56.36%)
Return on assets (62.71%) (40.50%) (48.04%)
Return on invested capital (82.46%) (253.48%) 0.00%

Growth

Metric EVMN LXEO Biotechnology median
Revenue growth (TTM) — — 6.02%
EPS growth (last fiscal year) 75.23% 39.81% 30.26%
Revenue growth, 5-year CAGR — — 9.41%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric EVMN LXEO Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 11.68 13.89 4.72
Net debt to EBITDA 1.87 1.67 0.96

Dividend

Metric EVMN LXEO Biotechnology median
Dividend yield — — 0.08%
Payout ratio — — —

Size

Metric EVMN LXEO Biotechnology median
Market cap 215.22m 226.56m 132.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack